VVA : new therapeutic options? BMS october 2017 A Pintiaux
|
|
- Randolph Moore
- 5 years ago
- Views:
Transcription
1
2 VVA : new therapeutic options? BMS october 2017 A Pintiaux
3 Disclosures Member of the european board of TEVA without personal gain No conflict of interest for this presentation
4 VVA Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition that develops because of the decline of estrogen levels. Symptoms : vaginal dryness, irritation and dyspareunia increased urinary frequency, urgency, and urge incontinence Approximately 50% of postmenopausal women suffer from VVA symptoms Local vaginal estrogens represent the current standard of care for treatment of symptomatic VVA and are effective in alleviating symptoms of moderate -to-severe VVA.
5 For symptomatic vaginal atrophy that does not respond to self-care measures, estrogen treatment is the standard of care, typically with vaginally administered local estrogens.
6 VVA : Some significant barriers to treatment lack of knowledge about VVA reluctance to discuss symptoms with healthcare professionals safety concerns for hormonal or non hormonal treatment ( endocrine disruptors in some vaginal preparations) Contraindications to estrogen use and inconvenience Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013;5: North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20: Palacios S, Castelo-Branco C, Currie H, et al. Update of managementof genitourinary syndrome of menopause. A practical guide. Maturitas 2015;82:308 13
7 The estrogen selective estrogen receptor modulator (SERM) ospemifene A new oral therapy option for postmenopausal women with moderate or severe VVA Ospemifene acts by exerting a tissue-specific effect, including an estrogen agonist effect on the vaginal epithelium The efficacy and safety of ospemifene were established in 30 clinical trials, with 2471 subjects Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014; 11:
8 New oral therapy option for postmenopausal women A combined analysis of two phase III trials reported improvement in dyspareunia and vaginal dryness in three-quarters of women compared with 50% to 60% who received the placebo. Ospemifene has recently been approved by the European medicines Agency (EMA) to treat moderate-to-severe VVA in postmenopausal women who are not subject to local vaginal estrogen therapy. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015; 18:
9
10 Molecular Biology : Ospemifene Triphenylethylene derivative, structurally similar to tamoxifen, but without the 2- (dimethylamino)ethoxy region Removal of this region is associated with reduced agonistic activity in the uterus, and no effects on agonist activity in bone or the cardiovascular system The binding affinity of ospemifene for ER a and ER b was evaluated in a competitive binding assay ; ospemifene displaced labeled 17 - estradiol in a concentration-dependent manner B.S. Komm, S. Mirkin / Journal of Steroid Biochemistry & Molecular Biology 143 (2014)
11 Pharmacology Following oral administration, ospemifene reaches the peak median serum concentration in approximately 2 hours in fasting postmenopausal women. The bioavailability of ospemifene is increased two- to three-fold by food intake, hence it is recommended to be taken with food. Steady state concentrations were observed after 7 days. Ospemifene is metabolized by cytochrome P450 (CYP450) enzymes in the liver, and it has a half-life of 26 hours. Excreted in the feces (75%) and urine. In vivo experiments demonstrated that the metabolism of ospemifene was induced by rifampin and was inhibited by ketoconazole or fluconazole. Jae Jun Shin and Seul Ki KimJournal of Menopausal Medicine 2017;23:79-84 Koskimies P, Turunen J, Lammintausta R, Scheinin M.Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. Int J Clin Pharmacol Ther 2013; 51:
12 Preclinical AND Clinical Data Breast Bone Endometrium
13
14 Bone Endometrium Brain
15 Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. Thirty-nine patients were enrolled in the study. Two patients experienced one new UTI episode and the mean number of positive urine culture decreased significantly after 6 months (3.65 ± 2.12 vs 0.25 ± 0.17, p <.0001). The mean number of urinary infection symptoms decreased significantly after treatment; dysuria reduced (4.76 ± 2.45 vs 0.89 ± 1.12). Schiavi MC, Gynecol Endocrinol. 2017
16 Effects of ospemifene on vaginal epithelium of post-menopausal women. Thirty-two post-menopausal women undergoing surgical procedures were enrolled. Sixteen subjects taking ospemifene at the time of inclusion (OSP) were compared to 16 subjects not taking any hormone (CTL). OSP group showed thicker vaginal epithelium (349 ± 64 vs. 245 ± 53 μm, p <.001), higher proliferation index (212 ± 47 vs. 127 ± 28 Ki-67 + cells/mm, p <.001), higher epithelial (27.3 ± 3.1 vs ± 2.9 score, p <.001) and stromal (26.6 ± 4.9 vs ± 2.6 score, p <.001) ERα expression when compared to the CTL group. In postmenopausal women affected by VVA, 1 month intake of ospemifene is associated with an increased maturation, and ERα expression of the vaginal mucosa. Alvisi S, Gynecol Endocrinol. 2017
17 N. Bruyniks, N. Biglia, S. Palacios & A. O. Mueck (2017): Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy, Climacteric, DOI: /
18 N. Bruyniks, N. Biglia, S. Palacios & A. O. Mueck (2017): Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy, Climacteric, DOI: /
19 Safety In clinical trials with postmenopausal women, ospemifene had no adverse effects on the breast, and mammograms performed after 52 weeks of ospemifene were normal in all subjects of all groups. In a phase III trial of postmenopausal women,with a treatment period of 12 weeks, taking either ospemifene 30 mg or 60 mg or placebo : minimal change in the endometrial thickness, and their endometrial biopsy showed no cases of endometrial hyperplasia or carcinoma. Extension studies demonstrated no significant endometrial changes associated with the use of ospemifene for at least up to 1 year of treatment. The FDA concluded that ospemifene 60 mg per day was generally safe. Simon JA, Lin VH, Radovich C, Bachmann GA. One-yearlong-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20: Simon J, Portman D, Mabey RG, Jr. Long-term safety ofospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 2014; 77: Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20:
20 Side effects Hot flashes were the most frequently reported side effects of ospemifene, with reported occurrence of 2% in the placebo group and 7.2% in the ospemifene group The incidence rates of thromboembolic and hemorrhagic stroke were 0.72 and 1.45 per 1,000 women, respectively, in the ospemifene group and 1.04 and 0 per 1,000 women, respectively, in the placebo group. The incidence of deep vein thrombosis was 1.45 per 1,000 women in the ospemifene group and 1.04 per 1,000 women in the placebo group. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014; 11: Shionogi Inc. Osphena : prescribing package insert. Florham Park, NJ: Shionogi Inc.;2015.
21 Archer D, Menopause, Vol. 24, No. 10, 2017
22 Archer D, Menopause, Vol. 24, No. 10, 2017
23 Repurposing ospemifene for potentiating an antigen-specific immune response. Ospemifene induced expression of the key TH1 cytokines interferon gamma and interleukin-2 in vitro, which may be mediated by stimulating T-cells through phosphoinositide 3-kinase and calmodulin signaling pathways. In combination with an antigen-specific peptide cancer vaccine, ospemifene increased antigenspecific immune response and increased cytotoxic T-lymphocyte activity in tumor-bearing and nontumor-bearing mice. The pretreatment, intermittent, and chronic dosing schedules of ospemifene activate naive T-cells, modulate antigeninduced tolerance and reduce tumor-associated, pro-inflammatory cytokines, respectively. CONCLUSIONS: Taken together, ospemifene's dose response and schedule-dependent immune modulating activity offers a method of tailoring and augmenting the efficacy of previously failed antigen-specific cancer vaccines for a wide range of malignancies. Kao CJ, Menopause. 2017
24 DHEA
25 Oral DHEA for postmenopausal women: A review of the evidence little convincing data to support the use of oral DHEA therapy in healthy aging individuals to improve conditions synonymous with normal aging such as reduced sexual function or diminished wellbeing no serious adverse effects have been reported in short term studies insufficient documentation on the effect of DHEA on the breast and the endometrium Labrie and others have investigated the effects of DHEA on mammary tissue extensively in vitro and rodent model and consistently report an inhibitory effect on mammary carcinoma development Endometrial thickness did not increase in postmenopausal women during a 6-month study of 25mg oral DHEA daily or in a 12-month study of 50mg oral DHEA daily M. Panjari, S.R. Davis / Maturitas 66 (2010)
26 Effect of intravaginal DHEA in postmenopausal women a daily dose of one ovule of the following DHEA concentrations: 0.0%, 0.5%, 1.0% or 1.8% after 7 days of treatment, the maturation value of the vaginal epithelial cells was significantly increased while the vaginal ph was significantly decreased at all DHEA doses serum concentrations of estradiol and testosterone remained within the values found in normal postmenopausal women at all DHEA doses similar observations were made for serum androstenedione, estrone, estrone-sulfate and DHEA-sulfate. DHEA is transformed into both androgens and estrogens in the vagina and permits to exert benefits on all the three layers of the vaginal wall. F. Labrie et al. / Journal of Steroid Biochemistry & Molecular Biology 111 (2008)
27 Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance) Postmenopausal women with a history of breast or gynecologic cancer who had completed primary treatment, had no evidence of disease, and reported at least moderate vaginal symptoms were eligible Four hundred sixty-four women were randomized. Women could be on tamoxifen or an AI for at least 8 weeks, without plans to change treatment during the study. Women were not eligible for the study if they had prior pelvic surgery resulting in anatomical changes, had prior radiation to the pelvis, active vaginal infections, or had used any hormonal product (including soy or any compounded hormones) in the preceding 4 weeks. Debra L. Barton & Charles L. Loprinzi, Support Care Cancer 2017
28 Debra L. Barton & Charles L. Loprinzi, Support Care Cancer 2017
29 Debra L. Barton & Charles L. Loprinzi, Support Care Cancer 2017
30 Debra L. Barton & Charles L. Loprinzi, Support Care Cancer 2017
31 Belgian Menopause Society
Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationSummary of the risk management plan (RMP) for Senshio (ospemifene)
EMA/736568/2014 Summary of the risk management plan (RMP) for Senshio (ospemifene) This is a summary of the risk management plan (RMP) for Senshio, which details the measures to be taken in order to ensure
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationEvaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-004HR) in Menopausal Women with Moderate to Severe Dyspareunia
Evaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-4HR) in Menopausal Women with Moderate to Severe Dyspareunia Lisa Larkin, MD 1 ; Andrew M Kaunitz, MD 2 ; James Liu, MD
More informationMenopause Symptoms and Management: After Breast Cancer
Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationVaginal atrophy is a common condition
original article Oman Medical Journal [2017], Vol. 32, No. 1: 15 19 Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women Maitri Shah 1 *, Zalak Karena 1, Sangita V. Patel
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationTherapy and Sexual Health
Menopausal hormone therapy and sexual health Earn 3 CPD Points online Menopausal Hormone Therapy and Sexual Health Key messages Dr Tobie De Villiers Consultant Gynaecologist Panorama MediClinic Department
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationInnovations in the Management of Dyspareunia
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationNew Treatments for Vaginal Health. Sarah Azad, MD El Camino Women s Medical Group
New Treatments for Vaginal Health There s Hope Sarah Azad, MD El Camino Women s Medical Group The Genitrourinary Syndrome of Menopause (GSM) Problems with genital health secondary to the changes that occur
More informationLaser CO2: una terapia ambulatoriale innovativa nel trattamento delle disfunzioni sessuali femminili
Obstetrics and Gynaecology Unit Functional Unit of Urogynaecology Vita-Salute San Raffaele University and San Raffaele Hospital Milan Italy Laser CO2: una terapia ambulatoriale innovativa nel trattamento
More information-TherapeuticsMD will host a conference call at 8:00 AM EDT today-
FOR IMMEDIATE RELEASE TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY TM (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe
More information7 Potential risks of low-dose estrogen therapy have
pissn: 2288-6478, eissn: 2288-6761 https://doi.org/1.6118/jmm.18.24.1.1 Original Article Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis
More information9/26/2016. Disclosures. Genitourinary Syndrome of Menopause: Novel Term for Common Conditions. Objectives ISSWSH NAMS CONSENSUS CONFERENCE
Genitourinary Syndrome of Menopause: Disclosures Novel Term for Common Conditions Research, Consultant, and/or Speaker Risa Kagan, MD, FACOG, CCD, NCMP Clinical Professor, Department of Obstetrics, Gynecology,
More informationVaginal estrogen deficiency
DOI: 10.1111/tog.12539 The Obstetrician & Gynaecologist http://onlinetog.org 2019;21:37 42 Reviews Shirin Khanjani MD PhD MRCOG, a, * Nick Panay BSc FRCOG MFSRH b,c,d a Clinical Lecturer and Subspecialist
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationProcess of Aging. Manifestation of Estrogen and/or Androgen Loss: Symptoms Over Time. Estrogen Decrease and Its Impact on Sexual Functioning
Impact of Vulvovaginal Atrophy on Quality of Life and Sexuality Process of Aging physical health sexual activity Sexual function and aging desire androgen levels Michael L. Krychman MD Executive Director
More informationFractional CO 2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors
DOI 10.1007/s00404-016-4118-6 GYNECOLOGIC ONCOLOGY Fractional CO 2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors Annalisa Pieralli 1,2 Maria Grazia Fallani 1 Angelamaria
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationTissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg
Tissue-selective estrogen complexes for postmenopausal women BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg Effects of CEE in Post Menopausal Women with Hysterectomy CHD 0.91 ( 0.75-1.12 ) BC 0.77
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationSexual dysfunction: Is it all about hormones?
Sexual dysfunction: Is it all about hormones? Angelica Lindén Hirschberg, MD, PhD, Professor Department of Women s and Children s Health, Karolinska Institutet and Karolinska University Hospital, Stockholm,
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationCopyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
28 The Nurse Practitioner Vol. 41, No. 7 www.tnpj.com 2.0 CONTACT HOURS 1.0 CONTACT HOURS Genitourinary syndrome of menopause: A new name for an old condition Abstract: Genitourinary syndrome of menopause
More informationUse of vaginal estrogen in Danish women: a nationwide cross-sectional study
AOGS ORIGINAL RESEARCH ARTICLE Use of vaginal estrogen in Danish women: a nationwide cross-sectional study AMANI MEAIDI 1,, IRINA GOUKASIAN & OEJVIND LIDEGAARD 1 1 Department of Gynecology, Rigshospitalet
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationFemTouch Treatment for Improving Vulvovaginal Health
FemTouch Treatment for Improving Vulvovaginal Health Dr. M. Marziali MD PhD in Gynecology and Obstetric Introduction Vulvovaginal atrophy (VVA) accompanies the natural aging of the vagina and affects up
More informationDisclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent
17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,
More informationColumbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3
17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,
More informationThe Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The Study of Tamoxifen
More informationHaelle T. Changing the conversation about hormone therapy in menopause. Medscape, 2017; accessed
Pelvic PT Distance Journal Club: November 2018 (Moderator: MJ Strauhal PT, DPT, BCB- PMD) Topic: Why should pelvic PT s be knowledgeable of menopausal changes in the urogenital region and the history of
More information5. Summary of Data Reported and Evaluation
168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed
More informationDyspareunia: Best Practices in Counseling, Diagnosis, and Therapy
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationPostmenopausal vulvar and vaginal atrophy (VVA) is
Menopause: The Journal of The North American Menopause Society Vol. 24, No. 4, pp. 409-416 DOI: 10.1097/GME.0000000000000786 ß 2016 The Author(s). Published by Wolters Kluwer Health, Inc., on behalf of
More informationOSPHENA (ospemifene) tablets, for oral use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OSPHENA safely and effectively. See full prescribing information for OSPHENA. OSPHENA (ospemifene)
More informationOSPHENA (ospemifene) tablets, for oral use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OSPHENA safely and effectively. See full prescribing information for OSPHENA. OSPHENA (ospemifene)
More informationEndocrine Steroids 2. Signal transduction 3. Prostaglandins
Endocrine - 2 1. Steroids 2. Signal transduction 3. Prostaglandins Estrogen Menopause (pause in the menes) ["change of life" at about 50] - lack of estrogen. (Some hysterectomy or ovarian cancer surgeries
More informationDehydroepiandrosterone (DHEA, prasterone) is transformed
Menopause: The Journal of The North American Menopause Society Vol. 22, No. 12, pp. 1289-1295 DOI: 10.1097/GME.0000000000000470 ß 2015 by The North American Menopause Society Lack of effect of intravaginal
More informationSexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners
Sexual dysfunction in women with cancer: Navigating intimacy and intercourse between women and their partners Don S. Dizon, MD, FACP Clinical Co-Director, Gynecologic Oncology Founder and Director, The
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20150425 New Drug Update Duavee: a tissue-selective estrogen complex
More informationPostmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study
European Review for Medical and Pharmacological Sciences Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study M. ORIGONI,
More informationDHEA, a superior treatment option for vaginal atrophy and menopause symptoms in women
DHEA, a superior treatment option for vaginal atrophy and menopause symptoms in women Dr. Anna Cabeca With aging, menopause, and hormonal changes some 75% of post-menopausal women suffer from vaginal atrophy
More informationNAMS in the News 2016
NAMS in the News 2016 Menopause in the News This is great support showing that being sedentary is not only not good for your health, it is not good for your menopause symptoms, said Dr. JoAnn Pinkerton,
More informationOriginal Article INTRODUCTION
Original Article A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012 Pardis Hosseinzadeh,
More informationSAMPLE REQUEST FAX FORM Fax to
SAMPLE REQUEST FAX FORM Fax to 973-644-2386 To receive your samples of Osphena (ospemifene) tablets 60mg Only 1 sample fax form per HCP will be processed per calendar month Please Note: Incomplete request
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationEstetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief)
Estetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief) Prof Wulf H Utian Case Western Reserve University School of Medicine, Cleveland,
More informationOBSTETRICS & GYNECOLOGY
AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationNew Terminology Old Problem!
New Terminology Old Problem! Dr. Chevelta A. Smith Adjunct Professor of LECOM - OB/Gyn March 3, 2018 Discuss the reason behind the development of this new terminology Review the Old Terminology for which
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationPharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule
CLIMACTERIC, 2016 VOL. 19, NO. 2, 181 187 http://dx.doi.org/10.3109/13697137.2015.1136926 ORIGINAL ARTICLE Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule J.
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationLeslie R. Schover, PhD Department of Behavioral Science
Causes and Treatments of Low Sexual Desire in Breast Cancer Survivors Leslie R. Schover, PhD Department of Behavioral Science IMPORTANCE OF SEX TO BREAST CANCER SURVIVORS Livestrong 2006 Post-Treatment
More informationDepression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia
Depression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia Moyneur, Erick MA 1, Dea, Katherine MSc 1, Derogatis, Len PhD 2, Labrie, Fernand MD, PhD 3 1 StatLog
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationImvexxy (estradiol) NEW PRODUCT SLIDESHOW
Imvexxy (estradiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Imvexxy Generic name: Estradiol Pharmacological class: Estrogen Strength and Formulation: 4mcg, 10mcg; vaginal inserts Manufacturer: TherapeuticsMD,
More informationCurrent Topics in Hormone Replacement Therapy
Current Topics in Hormone Replacement Therapy Corey R. Babb, D.O., FACOOG, IF, NCMP Clinical Assistant Professor of Obstetrics and Gynecology Director of the Oklahoma State University Center for Women
More informationVulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations
CLINICAL OBSTETRICS AND GYNECOLOGY Volume 58, Number 3, 476 491 Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations AHINOAM LEV-SAGIE, MD Department of Obstetrics
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationAtrophy of the epithelial surface of the vaginal
Menopause: The Journal of The North American Menopause Society Vol. 23, No. 3, pp. 243-256 DOI: 10.1097/GME.0000000000000571 ß 2016 by The North American Menopause Society Efficacy of intravaginal dehydroepiandrosterone
More informationCancer in Women after Menopause
Cancer in Women after Menopause BELGIAN MENOPAUSE SOCIETY SEPTEMBER 19, 2009 A. Pintiaux ULg Gynaecological Uses of a New Class of Steroids : the Selective Progesterone Receptor Modulators BELGIAN MENOPAUSE
More informationEffects of menopause and hormone replacement therapy (HRT) on quality of life of women
Effects of menopause and hormone replacement therapy (HRT) on quality of life of women MD. Nguyen Thi Ngoc Phuong President of the Ho Chi Minh City Reproductive Endocrinology and Infertility Association
More informationOffering Tamoxifen Patients a Therapeutic OPTION
Soltamox (tamoxifen citrate) oral solution is indicated for the treatment of metastatic breast cancer in women and men; for the adjuvant treatment of node-positive breast cancer in postmenopausal women
More informationPreliminary Results after Four Years of MonaLisa Touch Treatments on Subjects with Genitourinary Syndrome of Menopause (GSM).
Preliminary Results after Four Years of MonaLisa Touch Treatments on Subjects with Genitourinary Syndrome of Menopause (GSM). Maurizio Filippini, M.D. - Miriam Farinelli, M.D. Gynaecological Endoscopy
More informationSERM Education Project Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across
SERM Education Project Reference List Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
More informationA Non-Hormonal Approach to Preventing Vulvovaginal Atrophy from Aromatase Inhibitors (AIs)
A Non-Hormonal Approach to Preventing Vulvovaginal Atrophy from Aromatase Inhibitors (AIs) Leslie R. Schover, PhD Department of Behavioral Science Funded by the Duncan Family Institute for Cancer Prevention
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationPractical recommendations for hormone replacement therapy in the peri- and postmenopause
CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationREJOICE Trial Data Presentation March 7, 2016
REJOICE Trial Data Presentation March 7, 2016 Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as we and our ) may contain forward-looking statements. Forward-looking statements
More informationEnergy Based Therapies in Gynecology and Vaginal Health: Update on CO 2
Energy Based Therapies in Gynecology and Vaginal Health: Update on CO 2 Eric R. Sokol MD Associate Professor of Obstetrics and Gynecology Associate Professor of Urology, by Courtesy Co-Director, Urogynecology
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationBy Milena Mincigrucci*, Costante Donati Sarti**, Angelamaria Becorpi***, Massimo Milani, and Gianluca Botta
Results of the VALYD* study A multicenter, epidemiological, observational, prospective study of vaginal atrophy and quality By Milena Mincigrucci*, Costante Donati Sarti**, Angelamaria Becorpi***, Massimo
More informationgenitourinary syndrome of menopause Objectives: To evaluate the safety and long-term efficacy of fractional CO2 laser
Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause Abstract Objectives: To evaluate the safety and long-term efficacy of fractional
More information2/28/2018. This presentation contains images of a graphic nature and are presented for medical education only. New Terminology Old Problem!
This presentation contains images of a graphic nature and are presented for medical education only. New Terminology Old Problem! Dr. Chevelta A. Smith Adjunct Professor of LECOM - OB/Gyn March 3, 2018
More informationThe Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis
Curr Obstet Gynecol Rep (2012) 1:50 58 DOI 10.1007/s13669-012-0007-6 MANAGEMENT OF MENOPAUSE (K-E HUANG, SECTION EDITOR) The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal
More informationMenopause and Post Gynecological Reproductive Care
Menopause and Post Gynecological Reproductive Care Nguyet-Cam Vu Lam, MD, FAAFP Associate Program Director St. Luke s Family Medicine Residency 1 Disclosure Dr. Nguyet-Cam Vu Lam has no conflict of interest,
More informationTAS-108: A Novel Steroidal Anti-Estrogen for Treatment of Breast Cancer
SRI Biosciences TAS-108: A Novel Steroidal Anti-Estrogen for Treatment of Breast Cancer Potential Indications Neo-adjuvant therapy for ER + primary breast cancers in premenopausal women Adjuvant therapy
More informationCase Presentation. Learning Objectives. Case Presentation. Case Presentation
Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy
More informationSexuality. The Pharmacologic Treatment of Female Sexual Dysfunction: Future Reality or Wishful Thinking? Risks of Opening the Medicine Cabinet
5 th Annual Meeting of the North American Menopause Society October 5, 4 Washington, DC Low Libido at Midlife: Will the Answer Ever Be in Our Medicine Cabinets? The Pharmacologic Treatment of Female Sexual
More information4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms
550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,
More informationPostmenopausal vulvar and vaginal atrophy (VVA)
Menopause: The Journal of The North American Menopause Society Vol. 24, No. 8, pp. 000-000 DOI: 10.1097/GME.0000000000000848 ß 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of
More informationOspemifene (Osphena ): A New Treatment for Dyspareunia and Vaginal Atrophy
ATERIA EDICA Volume 2, Issue 3 August 2013 Ospemifene (Osphena ): A New Treatment for Dyspareunia and Vaginal Atrophy Fallon Wu, PharmD candidate P ainful sexual intercourse, otherwise known as dyspareunia,
More informationLow sexual desire: Appropriate use of testosterone in menopausal women
Low sexual desire: Appropriate use of testosterone in menopausal women Low-dose testosterone treatment may be considered for HSDD in carefully selected menopausal women after standard therapies have been
More informationEfficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
Short Communication Obstet Gynecol Sci 2017;60(2):213-217 https://doi.org/10.5468/ogs.2017.60.2.213 pissn 2287-8572 eissn 2287-8580 Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationNEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN
ORIGINAL ARTICLE Tibolone Compliance and Efficacy in Women Living in Taiwan NEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN Kuan-Chong Chao*, Peng-Hui Wang, Ming-Shyen
More information